Genentech, CDER Spar Over Third-Party Views On Avastin Breast Cancer Claim
Executive Summary
Disagreements between Genentech and FDA’s Center for Drug Evaluation and Research over the scope of evidence to be allowed at the June 28-29 hearing on Avastin’s breast cancer indication have escalated into a heated debate over the relevance of external views.
You may also be interested in...
NCCN Guidelines Reaffirm Support For Avastin In Metastatic Breast Cancer
The influential NCCN Clinical Practice Guidelines for Oncology should retain its recommendation supporting use of Genentech/Roche’s Avastin (bevacizumab) in metastatic breast cancer, the National Comprehensive Cancer Network expert breast cancer panel voted 24-0, with 1 abstention, at its July 10-12 meeting. NCCN recommendations are often used by payers in establishing formulary and coverage policies.
NCCN Guidelines Reaffirm Support For Avastin In Metastatic Breast Cancer
The influential NCCN Clinical Practice Guidelines for Oncology should retain its recommendation supporting use of Genentech/Roche’s Avastin (bevacizumab) in metastatic breast cancer, the National Comprehensive Cancer Network expert breast cancer panel voted 24-0, with 1 abstention, at its July 10-12 meeting. NCCN recommendations are often used by payers in establishing formulary and coverage policies.
Accelerated Approval Program’s Future Is On The Line At Avastin Hearing
Genentech and FDA’s Center for Drug Evaluation and Research seem to agree on one thing when it comes to deciding whether Avastin’s (bevacizumab) metastatic breast cancer indication should be withdrawn – the integrity and intent of the agency’s accelerated approval program are at stake.